Healthy Neurons Research Articles

Degeneration specific NF-L immunoreactivity in spinal cord and brainstem 10 days post-cervical spinal cord contusion

We recently described a panel of novel antibodies to epitopes on the neurofilament light chain (NF-L) which are hidden in healthy neurons and their processes but specifically exposed during neurodegeneration ( doi.org/10.1101/2022.08.27.504533 ). We saw widespread immunopositivity for such antibodies in degenerating and degenerated processes in the rat spinal cord 1-5 days following cervical spinal cord injury (cSCI). Here we aimed to determine if such immunopositivity would persist at 10 days following cSCI. Male Sprague Dawley rats received laminectomy (n=3) or right unilateral contusion at C4 (n=3; 150kdyn; Infinite Horizon Impactor). Tissue was harvested 10 days post-SCI and stained with either Cresyl Violet for routine histology or for immunohistochemistry using mouse monoclonal antibody MCA-6H63, one of several novel antibodies binding to degeneration specific NF-L epitopes (EnCor Biotechnology Inc.). Spinal cord MCA-6H63 immunopositivity was not detected in spinal cords from the laminectomy group. Contusion produced the expected histopathology with ipsilateral grey and white matter disruption and some damage to the contralateral dorsal columns. Punctate labeling for MCA-6H63 was prominent at the lesion epicenter, as well as in the ipsilateral cord rostral and caudal to the injury, consistent with axonal degeneration. Sparse, punctate MCA-6H63 positivity was observed in the contralateral cervical white matter. Qualitatively, MCA-6H63 staining was most robust in the ventral and lateral white matter ipsilateral and caudal to the lesion. This location was consistent with ongoing Wallerian degeneration in prominent spinal tracts including spinothalamic, spinocerebellar, reticulospinal, vestibulospinal and raphespinal. Bilateral MCA-6H63 staining in the dorsal columns was present mostly rostral to the injury. Some MCA-6H63 staining was noted in the medulla, most prominently ipsilateral to the lesion. We conclude that at 10 days post-cSCI this novel NF-L antibody specifically identifies degenerating and degenerated axonal profiles. This is a promising technique in assessing neurodegeneration following SCI and other neurodegenerative diseases. R01HL139708-01A1 (DDF), R01 HL153140-01 (DDF), and EnCor Biotechnology Inc. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

The impact of selective and non-selective medial septum stimulation on hippocampal neuronal oscillations: A study based on modeling and experiments

Alzheimer's disease (AD) is a neurodegenerative disorder with a rising socioeconomic impact on societies. The hippocampus (HPC), which plays an important role in AD, is affected in the early stages. The medial septum (MS) in the forebrain provides major cholinergic input to the HPC and has been shown to play a significant role in generating oscillations in hippocampal neurons. Cholinergic neurons in the basal forebrain are particularly vulnerable to neurodegeneration in AD. To better understand the role of MS neurons including the cholinergic, glutamatergic, and GABAergic subpopulations in generating the well-known brain rhythms in HPC including delta, theta, slow gamma, and fast gamma oscillations, we designed a detailed computational model of the septohippocampal pathway. We validated the results of our model, using electrophysiological recordings in HPC with and without stimulation of the cholinergic neurons in MS using designer receptors exclusively activated by designer drugs (DREADDs) in healthy male ChAT-cre rats. Then, we eliminated 75% of the MS cholinergic neurons in the model to simulate degeneration in AD. A series of selective and non-selective stimulations of the remaining MS neurons were performed to understand the dynamics of oscillation regulation in the HPC during the degenerated state. In this way, appropriate stimulation strategies able to normalize the aberrant oscillations are proposed. We found that selectively stimulating the remaining healthy cholinergic neurons was sufficient for network recovery and compare this to stimulating other subpopulations and a non-selective stimulation of all MS neurons. Our data provide valuable information for the development of new therapeutic strategies in AD and a tool to test and predict the outcome of potential theranostic manipulations.

The Parkinson-Associated Toxin Paraquat Shifts Physiological α-Synuclein Tetramers toward Monomers That Can Be Calpain-Truncated and Form Oligomers

Abnormal aggregation of α-synuclein (αS) is thought to initiate neuronal dysfunction and death in Parkinson disease (PD). In addition to higher-molecular-weight, oligomeric, and polymeric forms of αS associated with neurotoxicity and disease, recent findings indicate the occurrence of physiological tetrameric assemblies in healthy neurons in culture and in brain. Herein, the PD-associated neurotoxin paraquat reduced physiological tetramers and led to calpain-truncated monomers and an approximately 70-kDa apparent oligomer different in size from physiological αS multimers. These truncated and oligomeric forms could also be generated by calpain cleavage of pure, recombinant human αS invitro. Moreover, they were detected in the brains of tetramer-abrogating, E46K-amplified (3K) mice that model PD. These results indicate that paraquat triggers membrane damage and aberrant calpain activity that can induce a pathologic shift of tetramers toward an excess of full-length and truncated monomers, the accumulation of αS oligomers, and insoluble cytoplasmic αS puncta. The findings suggest that an environmental precipitant of PD can alter αS tetramer/monomer equilibrium, as already shown for several genetically caused forms of PD.

Potential Protective Function of Aβ42 Monomer on Tauopathies.

While soluble forms of amyloid-β (Aβ) and Tau work together to drive healthy neurons into a disease state, how their interaction may control the prion-like propagation and neurotoxicity of Tau is not fully understood. The cross-linking via disulfide bond formation is crucial for Tau oligomers to obtain stable conformers and spread between cells. This work thus focuses on how Aβ42 regulates this critical process. By studying the interactions between Aβ42 and TauPHF43, a construct that mimics the Tau R3 isoform, has a similar length to Aβ42, and contains one cysteine (Cys-322), we discovered that fresh Aβ42 could protect Tau against the formation of disulfide cross-linked dimers. We showed that the monomeric and small Aβ oligomers (the "nonamyloidogenic Aβ") efficiently disassembled tau dimers and heparin-induced Tau oligomers to recover Tau monomers. Interestingly, Aβ serves the role of an antioxidant to prevent disulfide bond formation, as supported by the experiments of Aβ with cystine. Furthermore, using cyclosporine A (CycA), a macrocyclic β-sheet disruptor, we demonstrated that targeting amyloidogenic Aβ with CycA does not affect the TauPHF43 disassembly driven by Aβ42. Separately, we assessed the initial toxicity of Aβ42 and TauPHF43 in acute brain slices and found that Aβ42 is more toxic than TauPHF43 or the two peptides combined. Our work highlights a potential protective role of Aβ42 monomers in AD that was previously overlooked while focusing on the mechanism behind Aβ42 aggregation leading to tau dysfunction.

Abl2 Kinase Differentially Regulates iGluRs Current Activity and Synaptic Localization.

Abelson non-receptor tyrosine kinases (Abl1 and Abl2) are established cellular signaling proteins, implicated in cytoskeletal reorganization essential for modulation of cell morphology and motility. During development of the central nervous system, Abl kinases play fundamental roles in neurulation and neurite outgrowth, relaying information from axon guidance cues and growth factor receptors to promote cytoskeletal rearrangements. In mature neurons, Abl kinases localize to pre- and postsynaptic compartments and are involved in regulation of synaptic stability and plasticity. Although emerging evidence indicates interchangeability of these isoforms in managing of cellular functions, in healthy adult neurons, Abl1 contribution is less elucidated, while Abl2 is required for optimal synaptic functioning. Our previous study demonstrated compartmentalization of Abl1 to the presynapse and Abl2 to the postsynapse and characterized their modulatory effect on spontaneous excitatory synaptic transmission. Here, we further delineate the role of Abl2 on regulation of the postsynaptic component of miniature excitatory postsynaptic current (mEPSC). Our findings show that both acute and prolonged activation of Abl2, in line with reduction of mEPSC amplitude, also decrease AMPA and NMDA current amplitudes. In contrast with the current-detrimental effect, prolonged Abl2 activity stabilizes spines, particularly contributing to maintenance of active synapses at distal (perhaps apical) segments of dendrites. Hence, we propose that attenuation of ion currents via ionotropic glutamatergic receptors by Abl2 kinase derives from either reduction of the receptor sensitivity for glutamate or is due to alteration of channel gating mechanisms. Abl2 and excitatory postsynapses: Abl2 expression level affects active excitatory synapse density on distal dendrites, while Abl2 activity impacts current density through AMPA and NMDA receptors.

Diminished motor neuron activity driven by abnormal astrocytic EAAT1 glutamate transporter activity in spinal muscular atrophy is not fully restored after lentiviral SMN delivery.

Spinal muscular atrophy (SMA) is characterized by the loss of the lower spinal motor neurons due to survival motor neuron (SMN) deficiency. The motor neuron cell autonomous and non-cell autonomous disease mechanisms driving early glutamatergic dysfunction, a therapeutically targetable phenotype prior to motor neuron cell loss, remain unclear. Using microelectrode array analysis, we demonstrate that the secretome and cell surface proteins needed for proper synaptic modulation are likely disrupted in human SMA astrocytes and lead to diminished motor neuron activity. While healthy astrocyte conditioned media did not improve SMA motor neuron activity, SMA motor neurons robustly responded to healthy astrocyte neuromodulation in direct contact cultures. This suggests an important role of astrocyte synaptic-associated plasma membrane proteins and contact-mediated cellular interactions for proper motor neuron function in SMA. Specifically, we identified a significant reduction of the glutamate Na+ dependent excitatory amino acid transporter EAAT1 within human SMA astrocytes and SMA lumbar spinal cord tissue. The selective inhibition of EAAT1 in healthy co-cultures phenocopied the diminished neural activity observed in SMA astrocyte co-cultures. Caveolin-1, an SMN-interacting protein previously associated with local translation at the plasma membrane, was abnormally elevated in human SMA astrocytes. Although lentiviral SMN delivery to SMA astrocytes partially rescued EAAT1 expression, limited activity of healthy motor neurons was still observed in SMN-transduced SMA astrocyte co-cultures. Together, these data highlight the detrimental impact of astrocyte-mediated disease mechanisms on motor neuron function in SMA and that SMN delivery may be insufficient to fully restore astrocyte function at the synapse.

Small molecule targeting long noncoding RNA GAS5 administered intranasally improves neuronal insulin signaling and decreases neuroinflammation in an aged mouse model

Shifts in normal aging set stage for neurodegeneration and dementia affecting 1 in 10 adults. The study demonstrates that lncRNA GAS5 is decreased in aged and Alzheimer’s disease brain. The role and targets of lncRNA GAS5 in the aging brain were elucidated using a GAS5-targeting small molecule NPC86, a frontier in lncRNA-targeting therapeutic. Robust techniques such as molecular dynamics simulation of NPC86 binding to GAS5, in vitro functional assays demonstrating that GAS5 regulates insulin signaling, neuronal survival, phosphorylation of tau, and neuroinflammation via toll-like receptors support the role of GAS5 in maintaining healthy neurons. The study demonstrates the safety and efficacy of intranasal NPC86 treatment in aged mice to improve cellular functions with transcriptomic analysis in response to NPC86. In summary, the study demonstrates that GAS5 contributes to pathways associated with neurodegeneration and NPC86 has tremendous therapeutic potential to prevent the advent of neurodegenerative diseases and dementias.

Mitochondrial dysfunction mediates neuronal cell response to DMMB photodynamic therapy

Photodynamic therapy (PDT) is a process in which a photosensitizer (PS) is exposed to specific wavelengths and generates reactive oxygen species (ROS) which act within nanometers. The low invasive nature and directed cytotoxicity of this approach render it attractive to the treatment of different conditions, including the ones that affect the central nervous system (CNS). The effect of PDT on healthy neurons is one main concern over its use in the CNS, since neuronal-like cells were shown to be particularly sensitive to certain PSs. Among available PSs, 1,9-dimethyl-methylene blue (DMMB) stands out as being resistant to reduction to its inactive leuco form and by being able to produce high levels of singlet‑oxygen. In this study, we aimed to investigate DMMB photodamage mechanisms in the hippocampal cell line HT22. Our results demonstrate that DMMB-PDT decrease in cell viability was linked with an increase in cell death and overall ROS production. Besides, it resulted in a significant increase in mitochondrial ROS production and decreased mitochondria membrane potential. Furthermore, DMMB-PDT significantly increased the presence of acidic autolysosomes, which was accompanied by an increase in ATG1 and ATG8 homologue GaBarap1 expression, and decreased DRAM1 expression. Taken together our results indicated that mitochondrial and autophagic dysfunction underlie DMMB-PDT cytotoxicity in neuronal cells.

Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy

<abstract><p>A mathematical model was built using delay differential equations to investigate the effect of active and passive immunotherapies in delaying the progression of Parkinson's Disease. The model described the dynamics between healthy and infected neurons and alpha-synuclein with innate and adaptive immune responses. The model was examined qualitatively and numerically. The qualitative analysis produced two equilibrium points. The local stability of the free and endemic equilibrium points was established depending on the basic reproduction number, $ R_0 $. Numerical simulations were executed to show the agreement with the qualitative results. Moreover, a sensitivity analysis on $ R_0 $ was conducted to examine the critical parameters in controlling $ R_0 $. We found that if treatment is administered in the early stages of the disease with short time delays, alpha-synuclein is combated, inhibiting activated microglia and T cells and preserving healthy neurons. It can be concluded that administering time of immunotherapies plays a significant role in hindering the advancement of Parkinson's disease.</p></abstract>

Synaptosome microRNAs: emerging synapse players in aging and Alzheimer's disease.

Synaptosome microRNAs: emerging synapse players in aging and Alzheimer's disease.

Levodopa u terapiji Parkinsonove bolesti

January 2023 marks the 100th anniversary of the birth of Arvid Carlsson, a Swedish scientist, one of the three winners of the Nobel Prize in Medicine in 2000 "for proving that Dopamine is a brain neurotransmitter whose deficiency leads to the symptoms of Parkinson's disease". Levodopa therapy is one of the main achievements of neurology in the twentieth century, and Parkinson' s disease was the first disease in which a specific neurochemical deficiency was confirmed in defined regions of the brain, which forms the basis for rational, chemically supported therapy. The paper briefly reviews the most important achievements in the discovery of Dopamine and levodopa, as well as their functions in the development of Parkinson's disease. Dopamine synthesis, understanding of levodopa synthesis method, possibility of measuring Dopamine concentration in putamen and caudate and its loss in Parkinson' s disease, along with histochemical visualization of nigrostriatal pathway and animal lesion model, enabled understanding of the role of nigrostriatal Dopamine system in the development of Parkinson's disease symptoms. Part of the work is devoted to the metabolism of Dopamine in healthy dopaminergic neurons, and then to its functioning in dopaminergic neurons of Parkinson's disease patients. It is known that in Parkinson's disease, Dopamine deficiency occurs due to selective degeneration of nigrostriatal dopaminergic neurons. Their suffering is triggered by a cascade of events that included the action of potential toxins, the influence of susceptibility genes on the body's response to them, oxidative stress caused by mitochondrial dysfunction, dysfunction of the ubiquitous proteasomal system that leads to the accumulation of incorrectly "packaged" proteins, the exhaustion of the endoplasmic reticulum system and the activation of mycoglia that follows inflammatory process. These changes can lead to programmed cell death of dopaminergic neurons with consequent Dopamine deficiency and the development of PD. Special attention is paid to the consequences of neuron loss on the functioning of the remaining dopaminergic neurons and Dopamine receptors, with reference to the therapeutic motor complications that may arise on that occasion. The basic assumptions about the occurrence of therapeutic complications are still related to the pharmacokinetics of levodopa and the model of its delivery to the brain, which results in non-physiological, pulsatile stimulation of Dopamine receptors. Today's possibilities in achieving a more stable concentration of levodopa with existing strategies are presented, with an answer to the question of whether continuous stimulation can be achieved under the conditions of standard, regular patients' levodopa therapy. In the short final part, the position of levodopa in the guidelines and recommendations for treatment is commented. It is expected that L-dopa will remain the "gold standard" for the treatment of PD at least until the development of more potent and safer Dopamine agonists or the development of neuroprotective or neurorestorative therapies.

Dynamic and Functional Alterations of Neuronal Networks In Vitro upon Physical Damage: A Proof of Concept.

There is a growing technological interest in combining biological neuronal networks with electronic ones, specifically for biological computation, human-machine interfacing and robotic implants. A major challenge for the development of these technologies is the resilience of the biological networks to physical damage, for instance, when used in harsh environments. To tackle this question, here, we investigated the dynamic and functional alterations of rodent cortical networks grown in vitro that were physically damaged, either by sequentially removing groups of neurons that were central for information flow or by applying an incision that cut the network in half. In both cases, we observed a remarkable capacity of the neuronal cultures to cope with damage, maintaining their activity and even reestablishing lost communication pathways. We also observed-particularly for the cultures cut in half-that a reservoir of healthy neurons surrounding the damaged region could boost resilience by providing stimulation and a communication bridge across disconnected areas. Our results show the remarkable capacity of neuronal cultures to sustain and recover from damage, and may be inspirational for the development of future hybrid biological-electronic systems.

The Effect of Chlordiazepoxide Consumption on the Hippocampus of Neonatal Rats During Pregnancy

Background: Chlordiazepoxide is an anti-anxiety drug commonly used by young people and pregnant women to reduce anxiety. The adverse effects of this drug on cholinergic nervous system function have been demonstrated. Therefore, in this study, the effect of chlordiazepoxide consumption during pregnancy was evaluated on the rats infant hippocampus. Materials and Methods: Nine pregnant Wistar rats were randomly divided (n=3 per group) into control, experimental (daily intraperitoneal injection of chlordiazepoxide at a dose of 10 mg/kg for 21 days), and vehicle (same amount of normal saline) groups. Two weeks after birth, the neonate brains were removed from the skull and prepared for Nissl and TUNEL stainings. The expressions of pro- and anti-apoptotic genes were evaluated. Results: The number of healthy neurons in different areas of the neonatal hippocampus in the experimental group was significantly reduced compared to control and vehicle groups, and the number of apoptotic bodies was increased (P<0.05). However, there was no significant difference between the numbers of these cells in the control and vehicle groups. The expression of pro-apoptotic genes in the experimental group increased significantly compared to the control group instead of the expression of anti-apoptotic genes decreased significantly. Conclusion: Chlordiazepoxide during pregnancy can cause neuronal damage in the hippocampus of neonatal Wistar rats.

Polyubiquitination of Tau Increases Across Braak Stages in Alzheimer’s Disease

AbstractBackgroundThe proteolytic ubiquitin‐proteasome system (UPS) is a main control mechanism of tau degradation in eukaryotic cells. Although the UPS is an integral regulator for tau turnover in healthy neurons, preliminary data suggests that the pathological tau in Alzheimer’s Disease (AD) is polyubiquitinated. This is an intriguing conundrum where the polyubiquitinylation of tau does not result in the degradation of the protein by the UPS. This suggests that the capacity of the UPS is limited or that the UPS is unable to degrade this form of tau. In this study, we aim to validate this potential correlation between the polyubiquitination of tau and AD, which could perhaps provide more clarity on the specific mechanisms of toxicity for AD.MethodWe examined postmortem brain tissue (inferior temporal gyrus) of 11 cases across AD neuropathological spectrum (Table 1). All slides underwent multiplex immunofluorescence for four antibodies: NeuN (neurons), FK2 (to detect polyubiquitin), T231 (ptau), and GFAP (astroglia), followed by scanning and quantification on digital slides. We quantified the percentage of neurons positive for tau (T231) and polyubiquitination (FK2) and analyzed the spearman correlation and linear regression model (LRM) corrected by age on death and sex.ResultCases represent a spectrum of AD stage. As expected, the proportion of neurons with tau inclusions increase along AD progression. We failed to identify neurons positive for FK2 (polyubiquitination) in the absence of tau and neurons. Moreover, we observed a direct correlation between higher Braak Stages and proportion of neurons with polyubiquitin immunoprecipitations (Figure 1, ρ = 0.89, p = 2.33e‐4).ConclusionNeurons with polyubiquitin immunoprecipitations increase in number along the AD continuum. These neurons tend to accumulate phospho‐tau inclusions suggesting a polyubiquitination of tau in AD. Further studies are needed to identify the mechanisms underlying the lack of tau degradation by the UPS in this situation, which could lead to treatment opportunities for AD.

Lysosomal alterations and decreased electrophysiological activity in CLN3 disease patient-derived cortical neurons.

CLN3 disease is a lysosomal storage disorder associated with fatal neurodegeneration that is caused by mutations in CLN3, with most affected individuals carrying at least one allele with a 966 bp deletion. Using CRISPR/Cas9, we corrected the 966 bp deletion mutation in human induced pluripotent stem cells (iPSCs) of a compound heterozygous patient (CLN3 Δ 966 bp and E295K). We differentiated these isogenic iPSCs, and iPSCs from an unrelated healthy control donor, to neurons and identified disease-related changes relating to protein synthesis, trafficking and degradation, and in neuronal activity, which were not apparent in CLN3-corrected or healthy control neurons. CLN3 neurons showed numerous membrane-bound vacuoles containing diverse storage material and hyperglycosylation of the lysosomal LAMP1 protein. Proteomic analysis showed increase in lysosomal-related proteins and many ribosomal subunit proteins in CLN3 neurons, accompanied by downregulation of proteins related to axon guidance and endocytosis. CLN3 neurons also had lower electrophysical activity as recorded using microelectrode arrays. These data implicate inter-related pathways in protein homeostasis and neurite arborization as contributing to CLN3 disease, and which could be potential targets for therapy.

Cellular senescence profiling reveals distinct sub‐types of neurofibrillary tangle bearing neurons.

AbstractBackgroundNeurons with tau‐containing neurofibrillary tangles (NFTs) closely correlate with Alzheimer’s disease (AD) progression and severity. Our prior work determined that NFT‐bearing neurons undergo a change in cell fate consistent with cellular senescence. The goal of this project was to determine whether senescent NFT‐bearing neurons differ from quiescent NFT‐bearing neurons.MethodPostmortem human AD brains were analyzed using GeoMx (NanoString, Inc) digital spatial profiling (DSP). Region of interest (ROI) selection included the presence or absence of neuronally expressed AT8 (phosphorylated tau, NFTs) and/or p19 (senescence). NFTs with or without p19 expression were compared to healthy neurons from the same cases. The expression of 86 proteins associated with neuropathology, inflammation, autophagy and cell typing was determined for each ROI and immediate environment (Fig. 1a‐b).ResultNFT‐bearing neurons with p19 (senescent) were significantly different than NFT‐bearing neurons without p19 (quiescent). Senescent NFT‐bearing neurons appeared similar to neurons without tau pathology. In contrast quiescent NFT‐bearing neurons displayed signs of crisis (i.e. apoptosis). Additionally, we revealed significant differences in tau phosphorylation at multiple epitopes between the two classes of NFT‐bearing neurons (Fig. 1c‐h).ConclusionThese data indicate the presence of distinct NFT‐bearing neuron subtypes in AD. Our ongoing studies are investigating (i) whether senescent or quiescent NFTs are more closely associated with pathogenesis, (ii) the transition between neuronal quiescence to senescence and (iii) which tau species contribute to this cell fate decision (self‐sacrificing versus disease propagating). More broadly, these results will provide a better understanding of distinct tau species in neurodegeneration which is critically important to clinical studies that are increasingly relying on tau biomarkers to predict disease onset, progression and target engagement in clinical trials.

CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis.

Patient diversity and unknown disease cause are major challenges for drug development and clinical trial design for amyotrophic lateral sclerosis (ALS). Transgenic animal models do not adequately reflect the heterogeneity of ALS. Direct reprogramming of patient fibroblasts to neuronal progenitor cells and subsequent differentiation into patient astrocytes allows rapid generation of disease relevant cell types. Thus, this methodology can facilitate compound testing in a diverse genetic background resulting in a more representative population for therapeutic evaluation. Here, we used established co-culture assays with motor neurons and reprogrammed patient skin-derived astrocytes (iAs) to evaluate the effects of (SP-4-2)-[[2,2'-(1,2-dimethyl-1,2-ethanediylidene)bis[N-methylhydrazinecarbothioamidato-κN2 ,κS]](2-)]-copper (CuATSM), currently in clinical trial for ALS in Australia. Pretreatment of iAs with CuATSM had a differential effect on neuronal survival following co-culture with healthy motor neurons. Using this assay, we identified responding and non-responding cell lines for both sporadic and familial ALS (mutant SOD1 and C9ORF72). Importantly, elevated mitochondrial respiration was the common denominator in all CuATSM-responders, a metabolic phenotype not observed in non-responders. Pre-treatment of iAs with CuATSM restored mitochondrial activity to levels comparable to healthy controls. Hence, this metabolic parameter might allow selection of patient subpopulations best suited for CuATSM treatment. Moreover, CuATSM might have additional therapeutic value for mitochondrial disorders. Enhanced understanding of patient-specific cellular and molecular profiles could help improve clinical trial design in the future.

Effect of ivabradine on cognitive functions of rats with scopolamine-induced dementia

Alzheimer’s disease is among the challenging diseases to social and healthcare systems because no treatment has been achieved yet. Although the ambiguous pathological mechanism underlying this disorder, ion channel dysfunction is one of the recently accepted possible mechanism. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play important roles in cellular excitability and synaptic transmission. Ivabradine (Iva), an HCN blocker, is acting on HCN channels, and is clinically used for angina and arrhythmia. The current study aimed to investigate the therapeutic effects of Iva against scopolamine (Sco) induced dementia. To test our hypothesis, Sco and Iva injected rats were tested for behavioural changes, followed by ELISA and histopathological analysis of the hippocampus. Induced dementia was confirmed by behavioural tests, inflammatory cytokines and oxidative stress tests and histopathological signs of neurodegeneration, multifocal deposition of congo red stained amyloid beta plaques and the decreased optical density of HCN1 immunoreactivity. Iva ameliorated the scopolamine-induced dysfunction, the hippocampus restored its normal healthy neurons, the amyloid plaques disappeared and the optical density of HCN1 immunoreactivity increased in hippocampal cells. The results suggested that blockage of HCN1 channels might underly the Iva therapeutic effect. Therefore, Iva might have beneficial effects on neurological disorders linked to HCN channelopathies.

Effect of Sulpiride on Dopaminergic Synapse of Dorsal Hippocampus of Morphine-Treated Rats

Background: As previous studies show, several effects of morphine are induced by the dopaminergic system. Sulpiride is a dopamine D2 receptor (DAD2) antagonist widely used in clinics to treat DArelated disorders. DAD2 receptors are abundant at hippocampal cornu ammonis (CA1). Objectives: This study aimed to investigate the possible interaction of morphine and sulpiride on DA synapses in CA1. Materials & Methods: In this study, 48 Wistar rats weighing 220 to 250 g were used. These animals were classified into eight groups (6 rats per group): saline control group (1 mL/kg), morphine group (5 mg/kg), sulpiride groups alone (1, 2, and 4 mg/kg) and sulpiride groups (1, 2, and 4 mg/ kg)+morphine (5 mg/kg). Saline or substances were injected once intraperitoneally. After 48 h, the animals’ brains were removed under anesthesia and placed in 10% formalin for fixation. Then, 3- to 4-μm slices were cut from these tissues, and the DA synapse was examined by histochemistry and immunohistochemistry techniques. The data were statistically analyzed by the analysis of variance. Results: The control group had DA synapses and healthy neurons. A relative increase in DA synapses compared to the control group was observed in the morphine and single sulpiride groups. However, in sulpiride+morphine groups, DA synapses were reduced compared to morphine or sulpiride alone, but neurons were not destroyed. Conclusion: The interaction effect of sulpiride and morphine in the CA1 region may decrease DA synapses.

Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach

This paper aims to mathematically model the dynamics of Parkinson’s disease with therapeutic strategies. The constructed model consists of five state variables: healthy neurons, infected neurons, extracellular α-syn, active microglia, and resting microglia. The qualitative analysis of the model produced an unstable free equilibrium point and a stable endemic equilibrium point. Moreover, these results are validated by numerical experiments with different initial values. Two therapeutic interventions, reduction of extracellular α-syn and reduction of inflammation induced by activated microglia in the central nervous system, are investigated. It is observed that the latter has no apparent effect in delaying the deterioration of neurons. However, treatment to reduce extracellular α-syn preserves neurons and delays the onset of Parkinson’s disease, whether alone or in combination with another treatment.